AC Immune SA (ACIU) - Financial and Strategic SWOT Analysis Review

  • ID: 4395067
  • SWOT Analysis
  • 49 pages
  • GlobalData
  • AC Immune SA
1 of 5

FEATURED COMPANIES

  • AbbVie
  • Araclon Biotech
  • Axon Neurosciences
  • Novartis AG
  • MORE
AC Immune SA (ACIU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

AC Immune SA (AC Immune) is a biopharmaceutical company that develops products for treating neurodegenerative diseases. It discovers, designs and develops innovative proprietary medicines to prevent, diagnose and treat neurodegenerative diseases associated with protein misfolding. The company develops drugs based on its two proprietary technology platforms, SupraAntigen and Morphomer. These technology platforms aid in the design, discovery and development of antibodies, small molecules and vaccines. AC Immune’s product pipeline includes nine therapeutic product candidates and three diagnostic product candidates. The company’s lead product candidate, crenezumab is an anti-Abeta antibody being developed in Phase III in collaboration with Genentech for treating Alzheimer’s disease. AC Immune is headquartered in Lausanne, Switzerland.

AC Immune SA Key Recent Developments

May 02, 2018: AC Immune Reports First Quarter 2018 Financial Results and Corporate Update
Apr 05, 2018: AC Immune Announces the Selection of Tau Small Molecules for Clinical Development in Alzheimer's disease
Mar 20, 2018: AC Immune reports full-year 2017 financial results - successful first year as a public company
Feb 06, 2018: AC Immune to Participate in Two Investor Conferences and Provide Scientific Updates at AAT-AD/PD Conference
Dec 01, 2017: AC Immune Shares Insights from Key Opinion Leader Meeting on Tau as a Therapeutic and Diagnostic Target in Alzheimer's and other Neurodegenerative Diseases

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie
  • Araclon Biotech
  • Axon Neurosciences
  • Novartis AG
  • MORE
Section 1 - About the Company
  • AC Immune SA - Key Facts
  • AC Immune SA - Key Employees
  • AC Immune SA - Key Employee Biographies
  • AC Immune SA - Major Products and Services
  • AC Immune SA - History
  • AC Immune SA - Company Statement
  • AC Immune SA - Locations And Subsidiaries
  • Head Office
Section 2 - Company Analysis
  • AC Immune SA - Business Description
  • AC Immune SA - Corporate Strategy
  • AC Immune SA - SWOT Analysis
  • SWOT Analysis - Overview
  • AC Immune SA - Strengths
  • AC Immune SA - Weaknesses
  • AC Immune SA - Opportunities
  • AC Immune SA - Threats
  • AC Immune SA - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • AC Immune SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • AC Immune SA, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • AC Immune SA, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 02, 2018: AC Immune Reports First Quarter 2018 Financial Results and Corporate Update
  • Apr 05, 2018: AC Immune Announces the Selection of Tau Small Molecules for Clinical Development in Alzheimer's disease
  • Mar 20, 2018: AC Immune reports full-year 2017 financial results - successful first year as a public company
  • Feb 06, 2018: AC Immune to Participate in Two Investor Conferences and Provide Scientific Updates at AAT-AD/PD Conference
  • Dec 01, 2017: AC Immune Shares Insights from Key Opinion Leader Meeting on Tau as a Therapeutic and Diagnostic Target in Alzheimer's and other Neurodegenerative Diseases
  • Nov 13, 2017: AC Immune Reports Third Quarter 2017 Financial Results and Corporate Update
  • Oct 03, 2017: AC Immune Awarded Continuation of 2015 Grant from The Michael J. Fox Foundation for Parkinsons Research
  • Aug 22, 2017: AC Immune Discovers Next-generation Antibodies Focused On Neurodegenerative Diseases
  • Aug 09, 2017: AC Immune Reports Second Quarter 2017 Financial Results
  • Jul 10, 2017: AC immune provides seven updates on its pipeline and technology at the alzheimer's association international conference
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Contact
  • Disclaimer
List of Tables
  • AC Immune SA, Key Facts
  • AC Immune SA, Key Employees
  • AC Immune SA, Key Employee Biographies
  • AC Immune SA, Major Products and Services
  • AC Immune SA, History
  • AC Immune SA, Key Competitors
  • AC Immune SA, Ratios based on current share price
  • AC Immune SA, Annual Ratios
  • AC Immune SA, Annual Ratios
  • AC Immune SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • AC Immune SA, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • AC Immune SA, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • AC Immune SA, Performance Chart (2013 - 2017)
  • AC Immune SA, Ratio Charts
  • AC Immune SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • AC Immune SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Novartis AG
  • Axon Neurosciences
  • Araclon Biotech
  • AbbVie
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll